ArticlePDF Available

IVERMECTIN IN LONG-COVID PATIENTS A RETROSPECTIVE STUDY

Authors:
ORIGINAL ARTICLE
February 2021
DOI: 10.13140/RG.2.2.14189.51683
IVERMECTIN IN LONG-COVID PATIENTS
A RETROSPECTIVE STUDY
AUTHORS: Del Franco, Aroldo 1; Carvallo, Hector 2; Hirsch, Roberto 3
1 Neumologist, Mercante Public Hospital
2 Professor of Internal Medicine, U.A.I.
3 Professor of Infectology, U.B.A.
Buenos Aires, Argentina
ABSTRACT:
Long COVID convalescence has become a major issue in COVID infection.
The variety and magnitude of sequelae has, so far, baffled scientific community, and no
measure has proved to be both useful and reliable in diminishing and/or shortening it.
We are summarising the outcomes in 856 patients previously admitted at a Public Hospital in
the Province of Buenos Aires, due to moderate/severe COVID infection, who surmounted the
infection and could be released later on.
We selected those whose symptoms, and mainly, the duration of them- could be attributed to
long convalescence (“long haulers”).
In them, a simple post-COVID treatment with ivermectin (IVM) was applied, thus provoking a
faster reduction of manifestations.
KEY WORDS: long COVID long haulers ivermectin
INTRODUCTION:
CURRENT KNOWLEDGE ON LONG COVID
There has been an increasing number of reports of COVID-19 symptoms extending beyond the
acute phase of infection, named "long COVID"; and its sufferers are known as “long haulers”.
A range of multiorgan complications following COVID-19 infection including respiratory,
cardiovascular, metabolic and renal impairments have also been hypothesised 1.
In a survey by the UK Government's Office for National Statistics in November, 2020, around
one in five people who tested positive for COVID-19 had symptoms that lasted for 5 weeks or
longer, and one in ten people had symptoms that lasted for 12 weeks or longer.
These figures equate to an estimated 186 000 individuals in England who had symptoms
persisting between 5 and 12 weeks 2.
Adults with severe illness who spend weeks in intensive care, often intubated, can experience
long-lasting symptoms, but that’s not unique to patients with COVID-19.
What’s unusual about the long haulers is that many initially had mild to moderate symptoms
that didn’t require lengthy hospitalization—if anylet alone intensive care.
In some organs, especially the lungs, those changes persist far past the point at which patients
have stopped shedding the virus 3.
The list of long hauler symptoms is long, wide and inconsistent.
The most common long hauler symptoms include (Fig. 1):
Coughing
Ongoing, sometimes debilitating, fatigue
Body aches
Joint pain
Shortness of breath
Loss of taste and smell even if this didn’t occur during the height of illness
Difficulty sleeping
Headaches
Brain fog
FIG. 1: LONG-TERM COVID EFFECTS (FROM SONIA VILLAPOL: LONG TERM EFFECTS OF COVID 19. THE
CONVERSATION. FEBRUARY, 2021)
Brain fog is among the most confusing symptoms for long haulers.
Patients report being unusually forgetful, confused or unable to concentrate.
This can happen to people who were in an intensive care unit for a while, but it’s relatively
rare.
Any well-trained Medical Doctor can tell from the way a COVID-patient talks- if he is still
suffering a brain fog, as ithe voice sounds like that of a nearly drunken person.
There's not a lot of information on long haulers, who only recently received attention from
experts because it’s also so new.
The vast majority of long haulers test negative for COVID-19.
One theory about patients with long-term COVID-19 symptoms is that the virus possibly
remains in their bodies in some small form.
Another theory is their immune systems continue to overreact even though the infection has
passed 4.
Based on the experience with other viral epidemics that are capable of causing a chronic-phase
of the disease, COVID-19 is difficult because of the diversity it exhibits in:
a- evading and affecting the human immune system,
b-the tissue tropism it exhibits based on ACE2 receptor density, and
c-its capability to run amok with multiple organ and systems.
Factors like the viral load, which may get eradicated or persist resulting from tissue budding of
SARS-CoV-2, appear to be possibly playing the main role in long-haulers (Fig. 2).
FIG. 2: PHISIOPATHOGENIC PATHWAYS TOWARS LONG COVID (FROM: ABDUL MANNAN BAIG: DELETERIOUS
OUTCOMES IN LONG-HAULER COVID-19)
Other factors like ACE2 density in tissues, vascular permeability, coagulation, and cytokine
activation cascade appear to determine a progression to a prolonged, less lethal but more
incapacitating clinical picture 5.
This could lead to a significant surge of people battling lasting illnesses and disabilities.
Symptoms lasting several weeks and impairing a person’s usual function should not be called
mild, neither should the subject be considered up to returning to usual activities so quickly.
Restoring such a subject to his ordinary labour tasks is a potential risk for both himself and his
fellow co-workers.
Defining and measuring recovery from COVID-19 should be more sophisticated than checking
for hospital discharge, or testing negative for active infection or positive for antibodies.
Once recovery is defined, we can differentiate COVID that quickly goes away from the
prolonged form 6.
The terms “COVID long haulers,” “long COVID,” and “Post COVID Syndrome,” have all been
used interchangeably in recent months to describe individuals who have been infected with
the SARS-CoV-2 and continue to experience symptoms after “recovery.”
However, these terms may be misleading, as they represent three different patient subsets
with prolonged symptoms, usually defined as greater than one month after COVID-19
infection.
These subsets include:
a-Critically-ill patients, almost all who have been admitted to intensive care, who, are expected
to have a lengthy recovery period (often months) and may have permanent organ damage,
particularly in the lung.
b-An undetermined number of patients, following mild or severe infection, who have organ
damage/dysfunction, such as myocarditis or an encephalopathy.
The long-range consequences are unclear.
c-Many patients, in some series estimated up to 10%, have prolonged, multisystem symptoms
with no evidence of organ damage or dysfunction.
These patients most often have severe exhaustion, headaches, myalgias, and mood and
cognitive disturbances with normal physical and laboratory findings.
This is the subset experiencing symptoms most similar to post-viral fatigue syndrome (PVFS),
chronic fatigue syndrome (CFS) also termed benign myalgic encephalomyelitis (BME) in the
UK, fibromyalgia and other related, poorly understood disorders associated with chronic
fatigue and pain.
In these conditions, there has been no strong evidence for organ damage or persistent and
significant immune/inflammatory abnormalities.
The confusion and controversy playing out online and among support groups for the third
subset of patients mirrors the misunderstandings of CFS over the past 40 years in both the
United States and the United Kingdom.
The symptoms are similar to those reported in PVFS or CFS.
However, dyspnea and loss of taste and smell appear to be much more common in Post COVID
Syndrome patients.
While PVFS is not new to the medical community, there is no clear path to treatment.
More important, there is still not enough knowledge about the exact causes or repercussions
of post-viral fatigue in recovering COVID-19 patients.
Ongoing symptoms reported by those recovering from COVID-19 infection should be taken
seriously and addressed accordingly.
Beyond doubt, there are a considerable number of individuals who have a post-viral syndrome
that really, in many respects, can incapacitate them for weeks and weeks following so-called
recovery and clearing of the virus, highly suggestive of myalgic encephalomyelitis/chronic
fatigue síndrome 7.
A new study published in the Annals of the American Thoracic Society, experts concede they
don’t know why some people who develop COVID-19 experience persistent symptoms after
the virus is no longer detectable in their body.
When healthcare providers order chest X-rays, CT scans, or other tests to look for potential
causes of long-haul symptoms, the results often come back negative.
Over 60 percent of the study participants said they had not yet returned to full health an
average of 75 days after their diagnosis.
However, only 4 percent showed signs of lung scarring on CT scans 8.
Those who emerged from life support at ICU, or beat severe cases of COVID-19 in the hospital,
are being home- visited and/or receive virtual house calls tend to post-hospital diagnoses,
medical checks as well as physical and occupational therapy for patients dealing with
symptoms impacting cognitive function as well as anxiety or depression 9.
Outpatient clinics that are dedicated to following up on lasting disabilities in the large number
of patients who previously had COVID-19 are opening in many hospitals, especially in areas
where large SARS-CoV-2 outbreaks have occurred.
However, this initiative implies a further burden on the health-care system in terms of human
and economic resources, in addition to conventional health-care services.
Unfortunately, these clinics are largely unaffordable in most low-income or middle-income
countries that have also been severely affected by the COVID-19 pandemic.
This is consistent with the syndemic nature of the COVID-19 pandemic, and has implications
for the long-term follow-up of COVID-19 sequelae, which in most instances should be
interpreted against a background of an array of non-communicable diseases and social and
income inequalities that exacerbate the adverse effects of each of these diseases in many
communities 10.
On the other hand, trying to make these patients recover by just prescribing “vitamins, deep
breath and plenty of rest” brings us back to the XIX century methods 11.
J. George characterized a group consisting of mostly outpatients: 90% of their cohort
experienced only a mild COVID-19 illness, yet one-third continue to have lingering effects.
Many of those individuals were young and have no pre-existing medical conditions, indicating
that even relatively healthy individuals may face long-term impacts from their illness.
Eraly in 2021, Wuhan studies of non-hospitalized patients have shown that anywhere from
35% to 50% of non-hospitalized patients had symptoms 2 to 4 months later.
Fatigue, breathing issues, and cardiac concerns like chest pain are common findings, as are
neurologic symptoms.
Of patients at the Center for Post-COVID Care at Mount Sinai with neurology referrals, about
65% come in with cognitive complaints or brain fog.
Brain fog means different things to different people, but usually it's some combination of
short-term memory issues, attention issues, and word-finding difficulty.
The University of Washington study followed 177 people with laboratory-confirmed SARS-CoV-
2 infection who completed questionnaires from August to November 2020, 3 to 9 months after
their COVID-19 onset (median 169 days).
Mean age was 48 and 57% were women. Hypertension was the most common comorbidity
(13%).
Across the cohort, 6.2% of participants were asymptomatic, 84.7% were outpatients with mild
illness, and 9.0% were hospitalized with moderate or severe disease. Patients completed
followup questionnaires a median of 169 days after COVID-19 onset.
Overall, 32.7% of outpatients and 31.3% of inpatients reported at least one persistent
symptom, most commonly fatigue (13.6%) and loss of sense of smell or taste (13.6%).
In addition, 13.0% reported other symptoms, including brain fog (2.3%).
Among outpatients and hospitalized patients, 30.7% reported worse health-related quality of
life compared with baseline; this figure was 12.5% for patients who never had overt COVID
symptoms.
About 8% of all participants said at least one activity of daily living suffered long-term
consequences, most commonly household chores.
Study limitations include small sample size, single study location, and potential bias from self-
reported symptoms 12.
Putting all the above-mentioned facts and theories in perspective, some obvious certainties
arise:
a- The real number of long-COVID patients is not clear
b- there is no close relation between the severity of the illness and the long COVID
c- the origin of this síndrome maybe related to the permanence of the virus in tissues either
than blood
d- there is no current treatment for reducing long COVID
CURRENT KNOWLEDGE ABOUT IVERMECTIN (IVM)
Ivermectin (IVM) is an antiparasitic (endodecticide), with nematicidal and ectoparasiticidal
properties. It is a macrocyclic lactone derived from avermectins, a group of highly active
endodecticidal antiparasitic agents isolated by fermentation of the soil microorganism
Streptomyces avermitilis.
It was discovered in 1960 in Japan by Satoshi Omura.
In 1981, William C. Cambell began the studies that allowed its veterinary use.
Both received the Nobel Prize in Physiology and Medicine in 2015.
In 1985, the French proved its usefulness in onchocerciasis in Africa. It was approved in 1997
by the FDA for treatments of: strongylidiasis and crusted scabies, in patients with AIDS.
In Human Medicine, it has been used in children from 5 years of age onwards, for the
management of ecto and enteroparasitosis.
Orally, in humans, it does not cross the blood-brain barrier.
It is contraindicated in pregnancy and lactation.
Recently, its viricidal effects on flaviviruses, dengue, Zica, Chikungunya, among others, have
been compiled.
Ivermectin is an inhibitor of the causative virus (SARS-CoV-2).
This activity is due to the dependence of many RNA viruses on IMPα / β1 during infection.
Recently, another mechanism of action has been proposed, assuming its role as an ionophore
agent.
Ionophores have many oxygen atoms internally, and are essential for binding cations and
transporting them through phospholipid bilayers (cell membranes; phospholipid capsid of the
virus).
As a consequence, it determines an ionic imbalance between the external and internal
environment, with the consequent osmotic.
These results, as a whole, demonstrated that ivermectin possesses antiviral action against
SARS-CoV-2 in vitro, with a single dose capable of controlling viral replication in 24-48 hours,
and the possibility of repeating it periodically.
Research has been added on other forms of action of IVM in the face of COVID disease, not
directly on the causative agent, but on the pathophysiological mechanisms through which its
deleterious activity develops (hyperinflammation and hypercoagulability).
All of the above is summarized in Figure 3.
FIG. 3: IVM MECHANISMS OF ACTION (FROM HIRSCH ROBERTO R, CARVALLO HECTOR E.: COVID 19 AND
IVERMECTIN PREVENTION AND TREATMENT UPDATE)
The effectiveness of IVM on pre and intraCOVID have already been proved in all our essays 13,
14, 15.
Though still neglected by the W.H.O., from the statistical point of view, IVM has already
proved its effectiveness against COVID 19 infection in all stages of the disease.
A meta-anaylisis also proved that an early treatment is far more effective than a delayed one.
The amount of data supporting the need to incorporate IVM amid the options of treatment
against COVID 19 is countless, and little by Little- more Countries and regions around the
World are including it in their schemes (Fig. 4).
FIG. 4: IVM USE AGAINST COVID 19 IN THE WORLD, FEBRUARY 2021 (FROM IVM META)
Our figures account for a 95.5 % reduction in the need of hospitalization, and a 95,6 %
reduction in death rate, when IVM treatment was applied at the early stages of the disease, in
consonance with existing data.
According to ours and other international data, roughly 11,000 lives worldwide could have
been saved daily, by simply adding IVM as the treatment offered to COVID 19 patients 16.
Statistically speaking, up to 10% of mild cases, and up to 40% of moderate cases, require
hospitalization.
For this reason, avoiding this instance is crucial, not only to decompress health systems, but
also to drastically lower their costs, which will result in the possibility of sustaining these
health policies indefinitely.
We also carried out a cost-survey to support what has been stated so far:
Hospitalization Costs, in Europe: Daily hospitalization (average): 2,932 euros
This figure doubles, if the ICU admission is considered.
IVM presentation of 20 ml (for two weeks): 5 euros 17.
MATERIAL AND METHOD:
We conducted a follow-up of 856 patients discharged from hospitalization at a Public Hospital
in Buenos Aires (Argentina), starting on July 2020 and still continuing.
All the patients included had not received IVM either before or during hospitalization.
Instead, they had been treated with corticosteroids, antibiotics, blood-thinners,
convalescents´plasma, etc.
The follow-up lasted as long as the patients were found to be free from symptoms and/or
sequelae.
Thus, some of them remain in weekly observation. For that reason, we divide this cohort into
two groups:
a- those patients who could finally be discharged even from ambulatory control (799), and
b- those patients who still have to be controlled, or referred to different subspecialties (57).
Beginnig by this SECOND GROUP, the long-lasting symptoms have been:
1) stress and/or paranoid disorders (39 from a total of 57)
2) memory loss (8 from a total of 57)
3) dysgeusia, defined as alterated sense of taste, mainly mixing salad and sweet sensations (6
from a total of 57)
4) fatigue (4 from a total of 57)
All these 57 patients had been at ICU for ver 10 days.
Now turning to the FIRST GROUP (799 subjects) it was composed of 411 male (51.44 %) and
388 female individuals (48.56 %). Fig. 5
The average age was 52,3 years, ranging from 21 to 82 years. Fig. 6
The prevailing symptoms were:
a- Coughing (not related to previous history of COLD)
b- Brain fog (not related to previous circulatory diseases and/or dementia)
c- Headaches (not related to high blood pressure or other common causes)
d- Persistent fatigue (not related to anemia and/or other causes)
e- Loss of taste and smell
f- Shortness of breath (same as “a” group)
g- Body/joint aches (not related to previous history of arthritis) Fig. 7
Some patients had two or more simultaneous symptoms.
All of the above-mentioned patients received IVM, ranging from 12 up to 18 mg per os, on a
weekly basis, until the symptoms disappeared, but no longer than 8 weeks (what happened
first).
Some of them also received polivitaminic compounds (the exact number lacking, because it
was an auto-prescription, but not exceeding from 12 patients).
The average time needed to get rid of those disturbing symptoms were 36 days, ranging from
21 to 69 days. Figs. 8 and 9
The side effects reported by the IVM-treated patients were:
1) Diarreic episodes in 5 patients
2) Abdominal pain in 2 patients
No cases of allergy were reported; neither were pregnant or lactating women among those
treated, thus IVm contraindications could be disregarded.
FIG. 5: SEX-RELATED DISTRIBUTION
FIG. 6: AGE-RELATED DISTRIBUTION
male
female
0
50
100
150
200
250
300
20-30 31-40 41-50 51-60 61-70 71-80
FIG. 7: SYMPTOMS REFERRED BY POST-COVID PATIENTS
FIG. 8: DAYS TO MAKE SYMPTOMS DISAPPEAR IN IVM-TREATED AND UNTREATED PATIENTS (in red and violet:
IVM; in blue: collected data from different surveys)
CONLUSIONS:
Long COVID includes a constellation of symptoms, that may be caused by the unobtrusive
persistence of virus in different tissues, and the subsicuent persistence of inflammatory and
coagulation disorders.
Since IVM has already proved to impair virus capacity to invade cells, and also to have immune
0
50
100
150
200
250
Coughing Brain Fog Headache Fatigue Hypog/osm Dyspnea
and clotting modulatory effects, there is a reasonable chance to diminish, shorten and even
completely correct almost all the symptoms by using IVM in the post COVID.
REFERENCES:
1) Office for National Statistics (ONS), UK; The prevalence of long COVID symptoms and
COVID-19 complications. Last updated: 16 December 2020
2) Priya Venkatesan: NICE guideline on long COVID. The Lancet Respiratory Medicine,
volume 9, issue 2, p129, february 01, 2021.
3) Rita Rubin: As Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts. JAMA.
2020; 324 (14):1381-1383. doi:10.1001/jama.2020.17709
4) UC Davis Health: Long haulers: Why some people experience long-term coronavirus
symptoms. Updated Feb. 8, 2021
5) Abdul Mannan Baig: Deleterious Outcomes in Long-Hauler COVID-19: The Effects of
SARS-CoV-2 on the CNS in Chronic COVID Syndrome. ACS Chem Neurosci. 2020 Dec 16;
11(24): 40174020. 2020 Dec 4. doi: 10.1021/acschemneuro.0c00725 PMCID:
PMC7724755 PMID: 33275404
6) Nisreen A. Alwan: A negative COVID-19 test does not mean recovery. Nature 584, 170
(2020) doi: https://doi.org/10.1038/d41586-020-02335-z
7) Jennifer Lutz: COVID Long Haulers: Symptoms and Connections to Post Viral Fatigue
and Organ Damage. Practical Pain Management. December 22, 2020
8) Liam Townsend et al.: Persistent Poor Health Post-COVID-19 Is Not Associated with
Respiratory Complications or Initial Disease Severity.
9) Jim aroune: 'Long Haulers': URMC Treating Lingering COVID Symptoms in Coronavirus
Survivors. Spectrum Helth News, Rochester. JAN. 07, 2021
10) Monica Cortinovis, Norberto Perico and Giuseppe Remuzzi: Long-term follow-up of
recovered patients with COVID-19. The Lancet. January 08,
DOI:https://doi.org/10.1016/S0140-6736(21)00039-8 (2021)
11) Aaron B. Holley: Treating Post-COVID Fatigue and Dyspnea; Deep Breaths and Plenty of
Rest. Medscape - Feb 19, 2021.
12) Judy George: Study Puts Numbers to 'Long COVID' Duration, Prevalence. MedPage
Today February 19, 2021
13) Carvallo Héctor, Hirsch Roberto, Farinella María Eugenia: Safety and efficacy of the
combined use of ivermectin, dexamethasone, enoxaparin and aspirin against covid 19.
medRxiv preprint September 15, 2020. doi:
https://doi.org/10.1101/2020.09.10.20191619
14) Carvallo Héctor, Hirsch Roberto, Alkis Psaltis, Contreras Veronica: Study of the Efficacy
and Safety of Topical Ivermectin + IotaCarrageenan in the Prophylaxis against COVID-
19 in Health Personnel. Journal of Biomedical Research and Clinical Investigation.
November 17, 2020. DOI: https://doi.org/10.31546/2633-8653.1007
15) Hirsch Roberto R, Carvallo Hector E.: Covid 19 and Ivermectin Prevention and
Treatment Update. Inf Dis Trav Med. 2020; 4: 1-4.
16) Alonso, Luis; Bracho Colina; Wilmer; Carvallo; Hector; Del Franco, Aroldo; Hirsch,
Roberto; Salgado, Antonio; and Seraj, Sanjid.: Ivermectin in covid 19 patients: a
multicenter, restrospective study. Researchgate. January 2021 DOI:
10.13140/RG.2.2.19384.57603
17) Carvallo, Hector E.; Matozza, Francesco; Hirsch, Roberto R.: Covid Pandemic and
Repurposed Drugs: How much is a human life? Feb 2021
https://www.researchgate.net/publication/349141261
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Abstract The number of new COVID 19 contagions and related deaths is increasing worldwide. Our early protocols (NCT04425850 and NCT04425863) duly submitted and released through the National Library of Medicine (USA) have given unmatched profs of efficacy and safety, but still await their time to become widespread. In the meantime, we have simplified their use, and added some extra tools to combat this permanent peril. The results of our further investigations are summarized below. Keywords: COVID19; Prophylaxis; Treatment; Update
Article
Full-text available
Rationale: Much is known about the acute infective process of SARS-CoV-2, the causative virus of the COVID-19 pandemic. The marked inflammatory response and coagulopathic state in acute SARS-CoV-2 may promote pulmonary fibrosis. However, little is known of the incidence and seriousness of post-COVID pulmonary pathology. Objectives: We describe respiratory recovery and self-reported health following infection at time of outpatient attendance. Methods: Infection severity was graded into three groups: (i) not requiring admission, (ii) requiring hospital admission, and (iii) requiring ICU care. Participants underwent chest radiography and six-minute-walk test (6MWT). Fatigue and subjective return to health were assessed and levels of C-reactive protein (CRP), interleukin-6, soluble CD25 and D-dimer were measured. The association between initial illness and abnormal chest x-ray, 6MWT distance and perception of maximal exertion was investigated. Results: 487 patients were offered an outpatient appointment, of which 153 (31%) attended for assessment at a median of 75 days after diagnosis. 74 (48%) had required hospital admission during acute infection. Persistently abnormal chest x-rays were seen in 4%. The median 6MWT distance covered was 460m. Reduced distance covered was associated with frailty and length of inpatient stay. 95 (62%) felt that they had not returned to full health, while 47% met the case definition for fatigue. Ongoing ill-health and fatigue were associated with increased perception of exertion. None of the measures of persistent respiratory disease were associated with initial disease severity. Conclusions: This study highlights the rates of objective respiratory disease and subjective respiratory symptoms following COVID-19 and the complex multifactorial nature of post-COVID ill-health.
Research
Full-text available
The severe acute respiratory syndrome-coronavirus-2 pandemic has had devastating health and socio-economic implications worldwide. Epidemiologic data indicate that SARS-CoV2 is spread by respiratory droplets and contact. The lack of acquired human immunity to the virus and the absence of a vaccine, has meant that current management strategies aimed at virus containment through mask wearing, social distancing and enforced lockdowns. Although the World Health Organization recommends 1,5 meters distancing to minimize transmission, recent studies have demonstrated high stability in aerosols and transmission distances up to 10 meters from emission sources . Health care workers are at particular risk from SARS-CoV-2. At present, no reliable prophylactic therapy exists to minimize their risk of acquiring SARS-CoV-2, and so they rely solely upon hand hygiene and the wearing of appropriate personal protective equipment (PPE), which is often in limited supply. Several studies have shown that the salivary gland and tongue express the ACE2 receptor, suggesting that the oral cavity is a perfect host for the invasion of COVID. Theoretically, agents that can inhibit viral adhesion and replication within the primary sites of viral entry (the nasal and oral cavity), may have a role in preventing SARS-CoV-2 transmission. Use of these agents prophylactically, would be especially beneficial in health care workers, particularly given the delay in results from viral RNA detection diagnostic test and the fact that many infected patients may have mild or no symptoms of the virus in the early stages. Two possible substances have been identified as candidate prophylactic agents in the fight against SARS-CoV-2. Carrageenans are naturally occurring extracts from the Rhodophyceas seaweed. Recently, the viricidal capacity of carrageenan has been reported, through inhibition of viral- host cell adhesion and early replication. Iota-carrageenan demonstrates potent antiviral activity in vitro, reducing rhinovirus, herpes simplex virus and the Japanese encephalitis virus reproduction and their cytopathic effects. Similarly, ivermectin has also been shown to posess antiviral activity against a whole host of RNA viruses (Zika, dengue, yellow fever, human immunodeficiency virus type 1). Thus, the combination of both products can provide an extra protection for those at risk of contagion.
Preprint
Full-text available
From the first outbreak in Wuhan (China) in December 2019, until today the number of deaths worldwide due to the coronavirus pandemic exceeds eight hundred thousand people and the number of infected people arises to more than 25 million. No treatment tested worldwide has shown unquestionable efficacy in the fight against COVID 19, according to NICE reports. We have designed an experimental treatment called IDEA based on four affordable drugs already available on the market in Argentina, based on the following rationale: -Ivermectin solution at a relatively high dose to lower the viral load in all stages of COVID 19 -Dexamethasone 4-mg injection, as anti-inflammatory drug to treat hyperinflammatory reaction to COVID-infection -Enoxaparin injection as anticoagulant to treat hypercoagulation in severe cases. -Aspirin 250-mg tablets to prevent hypercoagulation in mild and moderate cases Except for Ivermection oral solution, which was used in a higher dose than approved for parasitosis, all other drugs were used in the already approved dose and indication. Regarding Ivermectin safety, several oral studies have shown it to be safe even when used at daily doses much higher than those approved already. A clinical study has been conducted on COVID-19 patients at Eurnekian Hospital in the Province of Buenos Aires, Argentina. The study protocol and its final outcomes are described in this article. Results were compared with published data and data from patients admitted to the hospital receiving other treatments. None of the patient presenting mild symptoms needed to be hospitalized. Only one patient died (0.59 % of all included patients vs. 2.1 % overall mortality for the disease in Argentina today; 3.1 % of hospitalized patients vs. 26.8 % mortality in published data). IDEA protocol appears to be a useful alternative to prevent disease progression of COVID-19 when applied to mild cases and to decrease mortality in patients at all stages of the disease with a favorable risk-benefit ratio.
Article
Pandemic policy must include defining and measuring what we mean by mild infection. Pandemic policy must include defining and measuring what we mean by mild infection. “Symptoms lasting several weeks and impairing a person’s usual function should not be called mild.”
UK; The prevalence of long COVID symptoms and COVID-19 complications
Office for National Statistics (ONS), UK; The prevalence of long COVID symptoms and COVID-19 complications. Last updated: 16 December 2020
Long haulers: Why some people experience long-term coronavirus symptoms
  • Davis Uc
  • Health
UC Davis Health: Long haulers: Why some people experience long-term coronavirus symptoms. Updated Feb. 8, 2021
Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome
  • Baig Abdul Mannan
Abdul Mannan Baig: Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome. ACS Chem Neurosci. 2020 Dec 16; 11(24): 4017-4020. 2020 Dec 4. doi: 10.1021/acschemneuro.0c00725 PMCID: PMC7724755 PMID: 33275404
COVID Long Haulers: Symptoms and Connections to Post Viral Fatigue and Organ Damage. Practical Pain Management
  • Jennifer Lutz
Jennifer Lutz: COVID Long Haulers: Symptoms and Connections to Post Viral Fatigue and Organ Damage. Practical Pain Management. December 22, 2020